Jay M. Sosenko

14.2k total citations · 5 hit papers
129 papers, 9.3k citations indexed

About

Jay M. Sosenko is a scholar working on Endocrinology, Diabetes and Metabolism, Genetics and Surgery. According to data from OpenAlex, Jay M. Sosenko has authored 129 papers receiving a total of 9.3k indexed citations (citations by other indexed papers that have themselves been cited), including 106 papers in Endocrinology, Diabetes and Metabolism, 86 papers in Genetics and 80 papers in Surgery. Recurrent topics in Jay M. Sosenko's work include Diabetes Management and Research (88 papers), Diabetes and associated disorders (85 papers) and Pancreatic function and diabetes (77 papers). Jay M. Sosenko is often cited by papers focused on Diabetes Management and Research (88 papers), Diabetes and associated disorders (85 papers) and Pancreatic function and diabetes (77 papers). Jay M. Sosenko collaborates with scholars based in United States, Canada and United Kingdom. Jay M. Sosenko's co-authors include Andrew J.M. Boulton, Rayaz A. Malik, Jay S. Skyler, Eva L. Feldman, Roy Freeman, Vera Bril, Dan Ziegler, Joseph C. Arezzo, Jerry P. Palmer and Rodica Pop‐Busui and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Jay M. Sosenko

125 papers receiving 8.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Diabetic Neuropathy: A Position Statement by the American Diabetes Association

2016 1.6k citations Rodica Pop‐Busui, Andrew J.M. Boulton et al. Diabetes Care profile →
Diabetic Neuropathies

2005 1.4k citations Andrew J.M. Boulton, Jay M. Sosenko et al. Diabetes Care profile →
Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association

2015 735 citations Mark A. Atkinson, Peter A. Gottlieb et al. Diabetes Care profile →
Diabetic Somatic Neuropathies

2004 657 citations Andrew J.M. Boulton, Jay M. Sosenko et al. Diabetes Care profile →
Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis

2016 505 citations Jay S. Skyler, Jerry P. Palmer et al. Diabetes profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jay M. Sosenko United States	43	5.4k	3.8k	3.6k	2.5k	1.7k	129	9.3k
Bruce A. Perkins Canada	61	7.3k 1.4×	3.8k 1.0×	1.7k 0.5×	3.6k 1.5×	2.5k 1.4×	253	14.4k
Franco Folli Italy	60	3.6k 0.7×	4.2k 1.1×	2.7k 0.8×	2.7k 1.1×	1.2k 0.7×	198	12.9k
G. Pozza Italy	41	2.7k 0.5×	2.8k 0.7×	1.8k 0.5×	1.8k 0.7×	906 0.5×	301	7.5k
Rodica Pop‐Busui United States	58	5.1k 1.0×	2.5k 0.7×	1.1k 0.3×	5.0k 2.0×	3.0k 1.7×	228	13.6k
Rita Basu United States	54	5.2k 1.0×	2.9k 0.8×	1.2k 0.3×	2.6k 1.1×	467 0.3×	166	9.5k
Dennis K. Yue Australia	49	3.6k 0.7×	1.6k 0.4×	752 0.2×	1.3k 0.5×	392 0.2×	179	8.2k
Steven V. Edelman United States	46	4.3k 0.8×	1.7k 0.5×	1.0k 0.3×	2.0k 0.8×	375 0.2×	163	7.7k
Fausto Santeusanio Italy	52	4.7k 0.9×	1.8k 0.5×	1.4k 0.4×	1.6k 0.6×	334 0.2×	176	7.9k
Giovanni Ghirlanda Italy	49	2.4k 0.4×	2.7k 0.7×	707 0.2×	2.0k 0.8×	294 0.2×	207	8.0k
F. John Service United States	44	4.1k 0.8×	2.6k 0.7×	1.2k 0.3×	1.6k 0.7×	2.0k 1.1×	120	8.4k

Countries citing papers authored by Jay M. Sosenko

Since Specialization

Citations

This map shows the geographic impact of Jay M. Sosenko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jay M. Sosenko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jay M. Sosenko more than expected).

Fields of papers citing papers by Jay M. Sosenko

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jay M. Sosenko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jay M. Sosenko. The network helps show where Jay M. Sosenko may publish in the future.

Co-authorship network of co-authors of Jay M. Sosenko

This figure shows the co-authorship network connecting the top 25 collaborators of Jay M. Sosenko. A scholar is included among the top collaborators of Jay M. Sosenko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jay M. Sosenko. Jay M. Sosenko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sims, Emily K., David Cuthbertson, Lauric Ferrat, et al.. (2025). IA-2A positivity increases risk of progression within and across established stages of type 1 diabetes. Diabetologia. 68(5). 993–1004. 2 indexed citations

Ferrat, Lauric, Nicholas J. Thomas, Diane K. Wherrett, et al.. (2025). Contrasting Adult and Pediatric Populations in a Cohort of At-Risk Relatives in The T1D TrialNet Pathway to Prevention Study. Diabetes Care. 48(9). 1571–1580. 1 indexed citations

Sosenko, Jay M., David Cuthbertson, Laura M. Jacobsen, et al.. (2025). A Glucose Fraction Independent of Insulin Secretion: Implications for Type 1 Diabetes Progression in Autoantibody-Positive Cohorts. Diabetes Technology & Therapeutics. 27(3). 179–186.

Sims, Emily K., David Cuthbertson, Laura M. Jacobsen, et al.. (2024). Comparisons of Metabolic Measures to Predict T1D vs Detect a Preventive Treatment Effect in High-Risk Individuals. The Journal of Clinical Endocrinology & Metabolism. 109(8). 2116–2123. 4 indexed citations

Sosenko, Jay M., David Cuthbertson, Emily K. Sims, et al.. (2023). Phenotypes Associated With Zones Defined by Area Under the Curve Glucose and C-peptide in a Population With Islet Autoantibodies. Diabetes Care. 46(5). 1098–1105. 9 indexed citations

Sims, Emily K., et al.. (2023). 731-P: The Effect of Abatacept upon Glucose and C-Peptide Endpoints at One Year of Treatment and on Follow-up. Diabetes. 72(Supplement_1). 3 indexed citations

Sims, Emily K., David Cuthbertson, Jamie L. Felton, et al.. (2022). Persistence of β-Cell Responsiveness for Over Two Years in Autoantibody-Positive Children With Marked Metabolic Impairment at Screening. Diabetes Care. 45(12). 2982–2990. 5 indexed citations

Nathan, Brandon M., María J. Redondo, Heba M. Ismail, et al.. (2021). Index60 Identifies Individuals at Appreciable Risk for Stage 3 Among an Autoantibody-Positive Population With Normal 2-Hour Glucose Levels: Implications for Current Staging Criteria of Type 1 Diabetes. Diabetes Care. 45(2). 311–318. 24 indexed citations

Sims, Emily K., David Cuthbertson, Kevan C. Herold, & Jay M. Sosenko. (2021). The Deterrence of Rapid Metabolic Decline Within 3 Months After Teplizumab Treatment in Individuals at High Risk for Type 1 Diabetes. Diabetes. 70(12). 2922–2931. 14 indexed citations

10.

Redondo, María J., Megan Warnock, Ingrid Libman, et al.. (2021). TCF7L2 Genetic Variants Do Not Influence Insulin Sensitivity or Secretion Indices in Autoantibody-Positive Individuals at Risk for Type 1 Diabetes. Diabetes Care. 44(9). 2039–2044. 1 indexed citations

11.

Casagrande, Sarah Stark, Catherine C. Cowie, Jay M. Sosenko, et al.. (2020). The Association Between Heart Rate and Glycemic Status in the National Health and Nutrition Examination Surveys. The Journal of Clinical Endocrinology & Metabolism. 105(3). e858–e870. 7 indexed citations

12.

Leete, Pia, Roberto Mallone, Sarah J. Richardson, et al.. (2018). The Effect of Age on the Progression and Severity of Type 1 Diabetes: Potential Effects on Disease Mechanisms. Current Diabetes Reports. 18(11). 115–115. 45 indexed citations

13.

Evans‐Molina, Carmella, Emily K. Sims, Linda A. DiMeglio, et al.. (2018). β Cell dysfunction exists more than 5 years before type 1 diabetes diagnosis. JCI Insight. 3(15). 80 indexed citations

14.

Sims, Emily K., Renecia A. Watkins, Farooq Syed, et al.. (2016). Elevations in the Fasting Serum Proinsulin–to–C-Peptide Ratio Precede the Onset of Type 1 Diabetes. PMC. 4 indexed citations

15.

Sims, Emily K., Renecia A. Watkins, Farooq Syed, et al.. (2016). Elevations in the Fasting Serum Proinsulin–to–C-Peptide Ratio Precede the Onset of Type 1 Diabetes. Diabetes Care. 39(9). 1519–1526. 99 indexed citations

16.

Greenbaum, Carla J., Craig A. Beam, David Boulware, et al.. (2013). Fall in C-peptide during first 2 years from diagnosis: Evidence of at least two distinct phases from composite type 1 diabetes TrialNet data. Diabetes Technology & Therapeutics. 15. 12 indexed citations

17.

Greenbaum, Carla J., Craig A. Beam, David Boulware, et al.. (2012). Fall in C-Peptide During First 2 Years From Diagnosis. Diabetes. 61(8). 2066–2073. 235 indexed citations

18.

Sosenko, Jay M., Jeffrey L. Mahon, Lisa Rafkin, et al.. (2010). A comparison of the baseline metabolic profiles between Diabetes Prevention Trial-Type 1 and TrialNet Natural History Study participants. Pediatric Diabetes. 12(2). 85–90. 12 indexed citations

19.

Ferrannini, Ele, et al.. (2009). Progression to Diabetes in Relatives of Type 1 Diabetic Patients: Mechanisms and Mode of Onset. Diabetes. 59(3). 679–685. 110 indexed citations

20.

Sosenko, Jay M., Jerry P. Palmer, Lisa Rafkin‐Mervis, et al.. (2008). Glucose and C-Peptide Changes in the Perionset Period of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1. Diabetes Care. 31(11). 2188–2192. 62 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact